[1] C. Gromisch, M. Qadan, M. Albuquerque Machado, K. Liu, Y. Colson, and M. W. Grinstaff, “Pancreatic Adenocarcinoma: Unconventional Approaches for an Unconventional Disease,” Cancer Res., vol. 80, no. 16, pp. 3179–3192, Aug. 2020, doi: 10.1158/0008-5472.CAN-19-2731.
[2] B. Zhou et al., “Early detection of pancreatic cancer: Where are we now and where are we going?,” Int. J. Cancer, vol. 141, no. 2, pp. 231–241, Jul. 2017, doi: 10.1002/ijc.30670.
[3] P. Rawla, T. Sunkara, and V. Gaduputi, “Epidemiology of Pancreatic Cancer: Global Trends, Etiology and Risk Factors,” World J. Oncol., vol. 10, no. 1, pp. 10–27, Feb. 2019, doi: 10.14740/wjon1166.
[4] F. I. Macedo et al., “Survival Outcomes Associated With Clinical and Pathological Response Following Neoadjuvant FOLFIRINOX or Gemcitabine/Nab-Paclitaxel Chemotherapy in Resected Pancreatic Cancer,” Ann. Surg., vol. 270, no. 3, pp. 400–413, Sep. 2019, doi: 10.1097/SLA.0000000000003468.
[5] S. van Roessel et al., “International Validation of the Eighth Edition of the American Joint Committee on Cancer (AJCC) TNM Staging System in Patients With Resected Pancreatic Cancer,” JAMA Surg., vol. 153, no. 12, p. e183617, Dec. 2018, doi: 10.1001/jamasurg.2018.3617.
[6] L. Cong et al., “Tumor size classification of the 8 th edition of TNM staging system is superior to that of the 7 th edition in predicting the survival outcome of pancreatic cancer patients after radical resection and adjuvant chemotherapy,” Sci. Rep., vol. 8, no. 1, Art. no. 1, Jul. 2018, doi: 10.1038/s41598-018-28193-4.
[7] H. Kourie et al., “Characteristic and outcomes of patients with pathologic complete response after preoperative treatment in borderline and locally advanced pancreatic adenocarcinoma: An AGEO multicentric retrospective cohort,” Clin. Res. Hepatol. Gastroenterol., vol. 43, no. 6, pp. 663–668, Nov. 2019, doi: 10.1016/j.clinre.2019.03.007.
[8] Q. Dong et al., “Elevated serum CA19-9 level is a promising predictor for poor prognosis in patients with resectable pancreatic ductal adenocarcinoma: a pilot study,” World J. Surg. Oncol., vol. 12, p. 171, Jun. 2014, doi: 10.1186/1477-7819-12-171.
[9] H. Imaoka et al., “Post-adjuvant chemotherapy CA19-9 levels predict prognosis in patients with pancreatic ductal adenocarcinoma: A retrospective cohort study,” Pancreatol. Off. J. Int. Assoc. Pancreatol. IAP Al, vol. 16, no. 4, pp. 658–664, Aug. 2016, doi: 10.1016/j.pan.2016.04.007.
[10] A. Azizian et al., “CA19-9 for detecting recurrence of pancreatic cancer,” Sci. Rep., vol. 10, no. 1, Art. no. 1, Jan. 2020, doi: 10.1038/s41598-020-57930-x.
[11] S. Awad, A. M. Alkashash, M. Amin, S. J. Baker, and J. B. Rose, “Biochemical Predictors of Response to Neoadjuvant Therapy in Pancreatic Ductal Adenocarcinoma,” Front. Oncol., vol. 10, 2020, doi: 10.3389/fonc.2020.00620.
[12] P. Bailey et al., “Genomic analyses identify molecular subtypes of pancreatic cancer,” Nature, vol. 531, no. 7592, Art. no. 7592, Mar. 2016, doi: 10.1038/nature16965.
[13] K. L. Bryant, J. D. Mancias, A. C. Kimmelman, and C. J. Der, “KRAS: feeding pancreatic cancer proliferation,” Trends Biochem. Sci., vol. 39, no. 2, pp. 91–100, Feb. 2014, doi: 10.1016/j.tibs.2013.12.004.
[14] J. Kim et al., “Unfavourable prognosis associated with K‐ras gene mutation in pancreatic cancer surgical margins,” Gut, vol. 55, no. 11, pp. 1598–1605, Nov. 2006, doi: 10.1136/gut.2005.083063.
[15] O. Turrini, M. Gilabert, J. Ewald, V. Moutardier, J.-R. Delpero, and J.-L. Iovanna, “Resectable pancreatic head adenocarcinoma: Is R0 resection an illusion? Genetic evaluation of venous resection margin affirmed unrecognized disease,” J. Visc. Surg., vol. 154, no. 5, pp. 329–333, Oct. 2017, doi: 10.1016/j.jviscsurg.2017.05.009.
[16] S. J. Kim et al., “Prediction of Recurrence With KRAS Mutational Burden Using Ultrasensitive Digital Polymerase Chain Reaction of Radial Resection Margin of Resected Pancreatic Ductal Adenocarcinoma,” Pancreas, vol. 48, no. 3, pp. 400–411, Mar. 2019, doi: 10.1097/MPA.0000000000001255.
[17] E. Buscail et al., “CD63-GPC1-Positive Exosomes Coupled with CA19-9 Offer Good Diagnostic Potential for Resectable Pancreatic Ductal Adenocarcinoma,” Transl. Oncol., vol. 12, no. 11, pp. 1395–1403, Aug. 2019, doi: 10.1016/j.tranon.2019.07.009.
[18] E. Buscail et al., “High Clinical Value of Liquid Biopsy to Detect Circulating Tumor Cells and Tumor Exosomes in Pancreatic Ductal Adenocarcinoma Patients Eligible for Up-Front Surgery,” Cancers, vol. 11, no. 11, Oct. 2019, doi: 10.3390/cancers11111656.
[19] M. B. Amin et al., “The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more ‘personalized’ approach to cancer staging,” CA. Cancer J. Clin., vol. 67, no. 2, pp. 93–99, Mar. 2017, doi: 10.3322/caac.21388.
[20] A. McGuigan, P. Kelly, R. C. Turkington, C. Jones, H. G. Coleman, and R. S. McCain, “Pancreatic cancer: A review of clinical diagnosis, epidemiology, treatment and outcomes,” World J. Gastroenterol., vol. 24, no. 43, pp. 4846–4861, Nov. 2018, doi: 10.3748/wjg.v24.i43.4846.
[21] L. Buscail, B. Bournet, and P. Cordelier, “Role of oncogenic KRAS in the diagnosis, prognosis and treatment of pancreatic cancer,” Nat. Rev. Gastroenterol. Hepatol., vol. 17, no. 3, pp. 153–168, Mar. 2020, doi: 10.1038/s41575-019-0245-4.
[22] A. D. Rhim et al., “EMT and dissemination precede pancreatic tumor formation,” Cell, vol. 148, no. 1–2, pp. 349–361, Jan. 2012, doi: 10.1016/j.cell.2011.11.025.
[23] C. A. McIntyre et al., “Alterations in driver genes are predictive of survival in patients with resected pancreatic ductal adenocarcinoma,” Cancer, vol. 126, no. 17, pp. 3939–3949, Sep. 2020, doi: 10.1002/cncr.33038.
[24] B. Ielpo et al., “A comparative study of neoadjuvant treatment with gemcitabine plus nab-paclitaxel versus surgery first for pancreatic adenocarcinoma,” Surg. Oncol., vol. 26, no. 4, pp. 402–410, Dec. 2017, doi: 10.1016/j.suronc.2017.08.003.
[25] S. Gillen, T. Schuster, C. Meyer Zum Büschenfelde, H. Friess, and J. Kleeff, “Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages,” PLoS Med., vol. 7, no. 4, p. e1000267, Apr. 2010, doi: 10.1371/journal.pmed.1000267.
[26] J. He et al., “Is a Pathological Complete Response Following Neoadjuvant Chemoradiation Associated With Prolonged Survival in Patients With Pancreatic Cancer?,” Ann. Surg., vol. 268, no. 1, pp. 1–8, Jul. 2018, doi: 10.1097/SLA.0000000000002672.